CC 930
CC 930 Basic information
- Product Name:
- CC 930
- Synonyms:
-
- MCC930
- CC 930
- CC930
- CC-930
- Tanzisertib
- trans-4-[[9-[(3S)-Tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]cyclohexanol
- 4-[[9-[(3s)-oxolan-3-yl]-8-(2,4,6-trifluoroanilino)purin-2-yl]amino]cyclohexan-1-ol
- TANZISERTIB (CC-930)
- CAS:
- 899805-25-5
- MF:
- C21H23F3N6O2
- MW:
- 448.44
- Product Categories:
-
- MAPK
- Mol File:
- 899805-25-5.mol
CC 930 Chemical Properties
- Boiling point:
- 626.4±65.0 °C(Predicted)
- Density
- 1.63±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
- form
- Powder
- pka
- 15.05±0.40(Predicted)
- color
- Off-white to yellow
CC 930 Usage And Synthesis
Uses
Tanzisertib is a potent, selective, and orally active c-Jun amino-terminal kinase (JNK) inhibitor used for treatment of dermal fibrosis.
Biological Activity
Tanzisertib (CC-930, JNK-930, JNKI-1) has an ATP-competitive inhibitory effect on the phosphorylation of the JNK-dependent protein substrate c-Jun and all isoforms of JNK (Ki(JNK1) = 44 ± 3 nM, IC50(JNK1) = 61 nM, Ki(JNK2) = 6.2 ± 0.6 nM, IC50(JNK2) = 5 nM, IC50(JNK3) = 5 nM), selective inhibition of ERK1 and p38a with IC50 of 0.48 μM and 3.4 μM, respectively .
in vivo
In the acute PK-PD rat model of LPS-induced TNFα production, oral administration of 10 mg/kg and 30 mg/kg of CC-930 reduced the production of TNFα in vivo by 23% and 77%, respectively. CC-930 is well tolerated in vivo and its effect is proportional to dose.
target
| Target | Value |
| JNK3 (Cell-free assay) | 0.006 μM |
| JNK2 (Cell-free assay) | 0.007 μM |
| 0.061 μM |
IC 50
JNK3: 6 nM (IC50); JNK2: 7 nM (IC50); JNK1: 61 nM (IC50)
CC 930Supplier
- Tel
- sales@boylechem.com
- Tel
- 021-58950125
- info@chemexpress.com
- Tel
- 400-6206333 13167063860
- anhua.mao@aladdin-e.com
- Tel
- +1 (866) 930-6790
- info@adooq.com
- Tel
- 400-400-164-7117 18317119277
- product02@bidepharm.com